Magenta Therapeutics (MGTA) Stock Price, News & Analysis

Company Overview

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.68 to $0.76
• 50-Day Range: $0.36 to $0.76
• 52-Week Range: $0.32 to $2.07
• Volume: 376,000 shs
• Average Volume: 848,835 shs
• Market Capitalization: $42.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Magenta Therapeutics Stock Analysis - MarketRank™

Magenta Therapeutics scored higher than 16% of companies evaluated by MarketBeat, and ranked 862nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Magenta Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Magenta Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MGTA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Magenta Therapeutics does not currently pay a dividend.

Dividend Growth

Magenta Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.84

Short Interest

There is no current short interest data available for MGTA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Magenta Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Magenta Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.18% of the stock of Magenta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.53% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGTA Stock Analysis - Frequently Asked Questions

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) announced its earnings results on Thursday, November, 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02.

When did Magenta Therapeutics' stock split?

Magenta Therapeutics shares split on Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly created shares were issued to shareholders after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

When did Magenta Therapeutics IPO?

Magenta Therapeutics (MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), NIO (NIO), Outlook Therapeutics (OTLK), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MGTA
• CIK: 1690585
• Web: www.magentatx.com
• Phone: (857) 201-2700
• Fax: N/A
• Employees: 67
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-76,460,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.88%
• Return on Assets: -57.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.49
• Quick Ratio: 19.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.23 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 60,665,000
• Free Float: 51,456,000
• Market Cap: $42.44 million
• Optionable: Not Optionable
• Beta: 2.12